期刊文献+

特发性血小板减少性紫癜患者巨核细胞和血小板参数的探讨 被引量:15

Analysis of Megakaryocytes and Platelet Parameters of ITP Patients
下载PDF
导出
摘要 目的:探讨骨髓巨核细胞与外周血血小板参数的变化在特发性血小板减少性紫癜(ITP)鉴别诊断中的价值。方法:研究设ITP患者组(46例)、非ITP患者组(45例)和健康人对照组(48例),分别检测ITP和非ITP组患者骨髓中巨核细胞及外周血血小板参数及健康对照组外周血血小板参数;采用t检测进行统计学分析。结果:与非ITP组相比,ITP组患者骨髓中巨核细胞数量明显增加,其中颗粒巨、幼巨核细胞明显增加,产板巨核细胞明显减少,差异有统计学意义(P<0.01),而外周血血小板各参数2组间无差异(P>0.05)。ITP组和健康对照组相比,外周血小板数量和压积均明显降低,有统计学意义(P<0.01)。结论:骨髓巨核细胞数目、分类及外周血血小板各参数,对ITP的鉴别诊断具有一定的参考价值。 Objective: To investigate the value of bone marrow megakaryocyte( BMK) and peripheral platelet parameter changes in differential diagnosis of idiopathic thrombocytopenic purpura( ITP). Methods: The 91 patients were divided into 2 groups: ITP group( 46 cases) and non-ITP group( 45 cases),while 48 healthy volunteers were used as healthy controls. The parameters of BMK and peripheral platelets of ITP and non-ITP patients,and parameters of peripheral platelets of healthy controls were detected and compared. Results: As compared with non-ITP group,the BMK count in ITP group obviously increased,including the gramlar MK and proo-MK,while the MK producing platelets obviously dicreased with statistical difference( P < 0. 01); the platelet parameters in 2 groups did not show significant difference( P > 0. 05). As compared with healthy control group,the platelet level and PCT of peripheral blood in ITP group significantly decreased( P < 0. 01). Conclusion: The BMK level and platelet parameters,especially the platelet count and PCT have clinical value for differential diagnosis of ITP to a certain degree.
作者 谢军 刘彦慧
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2015年第5期1397-1399,共3页 Journal of Experimental Hematology
关键词 特发性血小板减少性紫癜 巨核细胞 血小板 idiopathic thrombocytopenic purpura megakaryocyte platelet
  • 相关文献

参考文献6

二级参考文献41

共引文献19

同被引文献131

  • 1秦平,陈峰,张春青,彭军,陈学良,侯明.大剂量地塞米松治疗慢性特发性血小板减少性紫癜的疗效观察[J].中华内科杂志,2005,44(6):451-452. 被引量:46
  • 2张磊,杨仁池,刘斌,卢士红,刘永泽,赵辉,任贺,韩忠朝.Bcl-x_L在原发性血小板增多症患者巨核细胞分化过程中的表达[J].中华血液学杂志,2006,27(1):50-52. 被引量:1
  • 3Drew Provan, Roberto Stasi, Adrian C, et al. International consensusreport on the investigation and management of primary immune thrombocytopenia[J]. Blood, 2010, 115: 168-186.
  • 4Xin-guang Liu, Ming Hou. Immune thrombocytopenia and B-cell-aActivating factor/a proliferation-inducing ligand [J]. Seminars in Hematology,2013,50:89-99.
  • 5Nishimoto T, Kuwana M, CD4+CD25+Foxp3+ regulatory T cells in the pathophysiology of immune thrombocytopenia [J].Seminars in Hematology,2013,50: 43 -49.
  • 6Xin Y, Zhang L, Chen Y, et al. The role of IL-23/Th17 pathway in patients with primary immune thrombocytopenia [J]. Plos One, 2015,10:1371.
  • 7Ferrara M, Capozzi L, Russo R. Effect of Helicobacter pylorieradication on platelet count in children with chronic idiopathic thrombocytopenic purpura [J].Hematology,2009,14(5): 282-285.
  • 8Takahashi T,Yujiri T,Shinohara K,et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of Hpyloriassociated chronic idiopathic thrombocytopenic purpura [J]. British Journal of Haematology, 2004,124:91-96.
  • 9Qiu JH, Shao 1, Zhou H, et al. Platelet desialylation is closely associated with cytotoxic T lymphocyte-mediated plateletdestruction in immune thrombocytopenia [J]. Blood, 2014, 124 (21): 463-463.
  • 10Wr6bel G,Dobaczewski G,Patkowski D,et al.Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia[J]. Pediatric Blood&Cancer,2006,47 (5) :729-730.

引证文献15

二级引证文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部